Most EDC platforms are built for drug trials, and that mismatch costs diagnostic sponsors real money. QIAGEN, which runs in vitro diagnostic studies inside working clinical laboratories, evaluated six or seven EDC providers before choosing Medrio, with two criteria driving the decision: keeping costs predictable and keeping study builds under QIAGEN’s own control rather than outsourcing configuration to the vendor.
The core problem with pharma-first EDC tools in a diagnostics context is form design. Lab environments generate data differently than a clinical site tracking a patient’s vital signs or adverse events, and forms built for one rarely transfer cleanly to the other. QIAGEN’s data management function, represented by Bouchra Dufour, PhD, Lead Senior Manager of Data Management,, needed forms their own staff could build and modify without developer involvement. That self-sufficiency matters because outside configuration adds both delay and cost every time a study changes, and IVD studies change. Dr. Sarah Johnson, VP Head of Clinical Affairs, was among the QIAGEN experts involved in selecting and implementing the platform.
Regulatory compliance adds another layer of complexity specific to this space. FDA’s March 2023 draft guidance confirmed that 21 CFR Part 11 requirements for electronic records and signatures apply directly to EDC systems used in clinical investigations, meaning sponsors, not vendors, bear the compliance burden. For a company like QIAGEN running diagnostic studies across busy labs, that puts a premium on an EDC whose audit trails and access controls are already structured to support Part 11 without custom engineering. The EDC market is growing at roughly 15.8% annually, reaching an estimated $2.71 billion in 2026, partly because more diagnostic sponsors face exactly this problem as regulators tighten expectations around electronic data integrity in IVD submissions.
QIAGEN published the operational details as a downloadable case study with Medrio, covering cost structure, form design for lab settings, and the support model. The concrete metric to watch from this arrangement is whether study build time actually stays in-house across protocol amendments, since that is where diagnostics sponsors typically lose the cost savings they expected from switching platforms.
Source link: https://medrio.com/case-studies/qiagen-ivd-diagnostic-studies-edc/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
